In a report released today, Alexander Nowak from Craig-Hallum maintained a Buy rating on QuidelOrtho (QDEL – Research Report). The company’s shares closed yesterday at $70.96.
Nowak covers the Healthcare sector, focusing on stocks such as QuidelOrtho, CareDx, and Guardant Health. According to TipRanks, Nowak has an average return of 0.0% and a 43.43% success rate on recommended stocks.
QuidelOrtho has an analyst consensus of Moderate Buy, with a price target consensus of $89.33, which is a 25.89% upside from current levels. In a report released today, RBC Capital also maintained a Buy rating on the stock with a $130.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $98.67 and a one-year low of $57.54. Currently, QuidelOrtho has an average volume of 518.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
QuidelOrtho (QDEL) Company Description:
Quidel Corp. engages in the development, manufacture and market of rapid diagnostic testing solutions. Its portfolio includes rapid immunoassays, cardiac immunoassays, specialized diagnostic solutions and molecular diagnostic solutions. The products are directly sold to end users and distributors and for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies and wellness screening centers. The company was founded in 1979 and is headquartered in San Diego, CA.
Read More on QDEL:
